Challenges and opportunities of CAR T-cell therapies for CLL *

Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment landscape of blood cancers. These engineered receptors which endow T cells with antibody-like target cell recognition combined with the typical T cell target cell lysis abilities. Introduced into the clinic in the 2010s, CAR T-cells have shown efficacy in chronic B lymphocytic leukemia (CLL), but a majority of patients do not achieve sustained remission. Here we discuss the current treatment landscape in CLL using small molecules and allogeneic stem cell transplantation, the niche CAR T-cells filled in this context, and what we have learned from biomarker and mechanistic studies. Several product parameters and improvements are introduced as examples of how the bedside-to-bench is translated into improved CAR T-cells for CLL. We hope to convey to our readers the crucial role translational medicine plays in transforming the treatment outcomes for patients with CLL and how this line of research is an essential component of modern medicine. (c) 2023 Elsevier Inc. All rights reserved.

Automated summary

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of blood cancers by endowing T cells with antibody-like target cell recognition and lysis abilities. In chronic B lymphocytic leukemia (CLL), CAR T-cells have shown efficacy, but sustained remission remains a challenge. This article discusses the current treatment landscape in CLL, the role of CAR T-cells, and the improvements made through translational medicine.